Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections
Open Access
- 30 September 2024
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (41)
Abstract
Despite much research, considerable data suggest that influenza virus remains a serious health problem because i) the effectiveness of current vaccines ranges only from 19% to 60%, ii) available therapies remain ineffective in advanced stages of disease, iii) death rates vary between 25,000 and 72,000/year in the United States, and iv) avian influenza strains are now being transmitted to dairy cattle that in turn are infecting humans. To address these concerns, we have developed zanDR, a bispecific small molecule that binds and inhibits viral neuraminidase expressed on both free virus and virus-infected cells and recruits naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens. Because the neuraminidase inhibition replicates the chemotherapeutic mechanism of zanamivir and oseltamivir, while rhamnose and DNP recruit endogenous antibodies much like an anti-influenza vaccine, zanDR reproduces most of the functions of current methods of protection against influenza virus infections. Importantly, studies on cells in culture demonstrate that both of the above protective mechanisms remain highly functional in the zanDR conjugate, while studies in lethally infected mice with advanced-stage disease establish that a single intranasal dose of zanDR not only yields 100% protection but also reduces lung viral loads faster and ~1,000× more thoroughly than current antiviral therapies. Since zanDR also lowers secretion of proinflammatory cytokines and protects against virus-induced damage to the lungs better than current therapies, we suggest that combining an immunotherapy with a chemotherapy in single pharmacological agent constitutes a promising approach for treating the more challenging forms of influenza.Keywords
This publication has 44 references indexed in Scilit:
- Tunable Multivalent Platform for Immune Recruitment to Lower Antigen Expressing CancersAngewandte Chemie International Edition, 2023
- Assessment of antibodies in the upper and lower human respiratory tract at steady state and after respiratory viral infectionClinical & Translational Immunology, 2023
- Influenza and antiviral resistance: an overviewEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase ReceptorAngewandte Chemie International Edition, 2016
- Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti‐Carbohydrate Antibodies to Tumor CellsChemBioChem, 2014
- Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agentsAntiviral Research, 2012
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Low-Dose Radiation Potentiates the Therapeutic Efficacy of Folate Receptor–Targeted Hapten TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumorsCancer Immunology, Immunotherapy, 2002
- Symptom pathogenesis during acute influenza: Interleukin‐6 and Other cytokine responsesJournal of Medical Virology, 2001